--RBC Cuts Price Target on Beam Therapeutics to $42 From $50, Maintains Sector Perform, Speculative Risk Rating

--RBC Cuts Price Target on Beam Therapeutics to $42 From $50, Maintains Sector Perform, Speculative Risk Rating

MT Newswires · 05/11/2023 03:55

Please log in to view news